|
Dr. Kumar is a co-founder of Onconova. He received his PhD in Molecular Biology from the University of Illinois, Chicago, and trained at the National Cancer Institute. He has held positions in R&D or management at Princeton University, Bristol-Myers Squibb, DNX (later Nextran, a subsidiary of Baxter) and Kimeragen (later Valigen), where he was President of the Genomics and Transgenics Division. Dr. Kumar has more than 50 publications spanning the areas of molecular oncology, transgenic animals, gene therapy and recombination. He is an inventor in 8 US Patents and many Patent applications. He co-edited the book "Molecular Basis of Human Cancer" in 1993. | 